Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NovaBay Pharmaceuticals has received $2.6m from partner Galderma for clinical advancement of NovaBay's "non-antibiotic, anti-infective" Aganocide compound NVC-422 as a topical formulation to replace traditional antibiotics to treat impetigo, a contagious skin infection.
Subscribe to our email newsletter
As part of the agreement, Galderma will carry on the ongoing NVC-422 clinical development program for impetigo and NovaBay will receive double-digit royalties on net sales of products.
NovaBay has withheld certain rights to Asian markets, onychomycosis, post surgical use and use in wound care and orphan drug indications.
Excluding Japan, NovaBay has also retained all rights in Asian markets to promote the products developed in hospitals and other healthcare institutions in North America.
Galderma and NovaBay enrolled first patient for impetigo treatment phase 2b global trial and are expecting the results from the trial in the first half of 2013.